The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
|Webcasts|September 29, 2022
A Guide to Importing and Exporting: Why Your Biological Samples Held Up in Customs
Author(s) Pyxant
Thu, Sep 29, 2022 11:00 AM EDT Are your biological samples held up in customs? Understand how to import and export biological samples with efficiency in this webcast.
Register free:
Event Overview:
Importing and exporting biological samples to and from a US bioanalytical lab requires the US government’s oversight to prevent the transportation of exotic diseases and the supplying of illegal markets. Pharma companies and bioanalytical partners must proactively work together to secure the correct import or export licenses or permits prior to shipment to ensure international samples arrive intact and on time. In this webcast, learn more about how the process is navigated to help you successfully plan your study’s timeline and avoid compromising your samples in transit.
Key Learning Objectives:
- Learn what US government agencies are involved in licensing/permitting the import and export of biological samples
- Determine which licenses/permits are required for which categories of biological materials
- Understand license/permit application requirements and approval lead times
Mark Vann
Operations Support Manager
Pyxant Labs
Mark Vann joined Pyxant Labs Colorado in 2018 and serves as the operations support manager, overseeing the inventory management of samples and compounds, international logistics, procurement, and special projects. Mark has worked with a variety of biotech and pharma companies to successfully import and export their biological samples.
Register free:
Related to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.